Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012–2023

• Xiaoyan Zhong ,

  Contributed equally to this work with: Xiaoyan Zhong, Jianchun Luo

  Roles Data curation

  Affiliation Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China

  ⨯
• Jianchun Luo ,

  Contributed equally to this work with: Xiaoyan Zhong, Jianchun Luo

  Roles Data curation

  Affiliation Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China

  ⨯
• Yuexi Huang,

  Roles Methodology

  Affiliation Department of Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China

  ⨯
• Shurong Wang ,

  Roles Methodology

  * E-mail: hyl3160131@163.com (YH); wangshurong011@swmu.edu.cn (SW)

  Affiliation Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China

  ⨯
• Yilan Huang

  Roles Writing – review & editing

  * E-mail: hyl3160131@163.com (YH); wangshurong011@swmu.edu.cn (SW)

  Affiliation Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China

  https://orcid.org/0000-0001-8672-0874

  ⨯